Abstract 2123P
Background
Immuno-nutritional scores like neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS) and controlling nutritional status (CONUT) have been developed to reflect the chronic inflammatory state and malnutrition induced by cancer, and to predict clinical outcomes. This study aims to investigate the prognostic value of these scores in hospitalized patients with lung cancer as we know that unscheduled admission in patients with cancer may imply organ fragility.
Methods
In this retrospective study, we examined patients with lung cancer and unscheduled hospitalizations that took place between June 2021 and May 2022 within the Medical Oncology Service of La Paz University Hospital in Madrid, Spain.
The optimal cutoff for continuous variables was evaluated with Youden index. Survival since admission was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox regression model to determine independent prognostic factors. Areas under the curve (AUCs) or ROCs were calculated to evaluate the discriminatory ability.
Results
We admitted 158 patients with a median age of 68 years, majority of male (66.5%) and stage IV predominance (84.8%). The median follow-up was 14.9 months. The median overall survival since admission was 3.3 months (95%CI: 1.86-7.74). The optimal cut-off value for NLR was calculated to be 6 (Youden index=0.2) and for PNI was 40 (Youden index=0.1). In univariate analysis, poorer survival was associated with NLR>6 (1.87 vs 7.40 months, p=0.006, HR 1.67, 95%CI 1.16-2.42) and PNI<40 (1.67 vs 4.97 months, p=0.044, HR 1.49, 95%CI 1.01-2.20) and was not associated with CONUT (p=0.70) or mGPS (p=0.067). In the multivariate analysis only NLR>6 was an independent prognostic factor (p=0.042, HR 1.61, 95%CI 1.02-2.57). The ROC curve to evaluate the discriminatory ability of 30-day mortality was only significant in the case of NLR>6 (p=0.035, AUC 0.599, 95%CI 0.51-0.69).
Conclusions
In our setting, NLR was the most robust score for estimating prognosis in hospitalized patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06